Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

Factor V Leiden Mutation Analysis

CPT: 81241
Updated on 10/25/2019
Print Share


  • Factor V Leiden DNA Test

Expected Turnaround Time

5 - 7 days

Related Documents

For more information, please view the literature below.

Procedures for Hemostasis and Thrombosis: A Clinical Test Compendium

Specimen Requirements


Whole blood or LabCorp buccal swab kit (buccal swab collection kit contains instructions for use of a buccal swab)


7 mL whole blood or LabCorp buccal swab kit

Minimum Volume

3 mL whole blood or two buccal swabs


Lavender-top (EDTA) tube, yellow-top (ACD) tube, or LabCorp buccal swab kit

Storage Instructions

Maintain specimen at room temperature.

Causes for Rejection

Frozen specimen; hemolysis; quantity not sufficient for analysis; improper container; one buccal swab; wet buccal swab

Test Details


Detection of Leiden (R506Q) mutation in factor V gene (OMIM 227400) associated with increased risk of thrombosis

Detection of Leiden (R506Q) mutation in factor V gene (OMIM 227400), causing increased risk of thrombosis

Detection of Leiden (R506Q) mutation in factor V gene (OMIM 227400) associated with increased risk of thrombosis


This test detects the factor V R506Q (Leiden) mutation and will help identify those individuals who are at increased risk of thrombosis; however, increased risk of thrombosis can be caused by a variety of genetic and nongenetic factors not screened for by this assay.

This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).


Allele-specific polymerase chain reaction (PCR)

Additional Information

Details of how the blood coagulation system is regulated have become well understood in recent years. Many of the abnormalities that cause some patients to have an increased risk for thrombosis have been defined at the molecular level. The poor anticoagulant response to activated protein C (APC), or APC resistance, that is found in up to 50% of patients with a family history of thrombosis, and in 3% to 8% of apparently normal individuals, was shown to correlate with the inheritance of a single-point mutation in the factor V gene. This mutation has been reported in patients with deep vein thrombosis, pulmonary embolus, central retinal vein occlusion, cerebral sinus thrombosis, and hepatic vein thrombosis. Ten percent to 20% of people with a first-time venous clot have this mutation. Strikingly, 40% of people younger than 50 with a first-time venous clot, and 60% of pregnant women with venous thrombosis have this mutation as well. Beyond the risk for thrombophilia, this mutation has also been associated with an increased risk for recurrent pregnancy loss, severe preëclampsia, fetal growth retardation, stillbirth, and placental problems (infarction and abruption).

The mutation is characterized by a guanine to adenine substitution at nucleotide 1691 in exon 10 of the factor V gene that replaces an arginine at codon 506 with a glutamine. It is designated as FV R506Q (Leiden), and confers resistance to inactivation by activated protein C. As a result, factor V persists in the circulation, leading to a mild hypercoagulable state. The Leiden mutation accounts for 90% to 95% of APC resistance. Heterozygous carriers of this mutation have a four- to eightfold increased risk of thrombosis. Individuals homozygous for the mutation (ie, they have a copy of the mutation on each chromosome) carry an 80- to 100-fold risk of thrombosis. All offspring of a factor V Leiden homozygote will inherit at least a single copy of the mutation. Genetic counseling is recommended for these patients.

The risk of venous thrombosis increases exponentially in patients with more than one risk factor, including age, surgery, oral contraceptive use, pregnancy, elevated homocysteine levels, or malignancy. A 2005 study reports malignancy carries a sevenfold increased risk for thrombosis, and that this effect is most pronounced for hematological malignancies, for recently diagnosed cancers, and/or for patients with distant metastases. Malignancy and genetic predisposition together may compound risk, as carriers of the factor V Leiden mutation who have cancer are more likely to develop thrombosis than mutation carriers without cancer. Other risk factors to be considered in the work-up for venous thrombosis include the G20210A mutation in the factor II (prothrombin) gene, mutations in the MTHFR gene, protein S and C deficiency, and antithrombin deficiencies. Anticardiolipin antibody and lupus anticoagulant analysis may be appropriate for certain patients, as well as homocysteine levels. Genetic counselors are available for health care providers to discuss results, and for information on how to order additional testing, if desired, at 800-345-4363.


Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005 Feb 9; 293(6):715-722. 15701913
College of American Pathologists Consensus Conference XXXVI: Diagnostic Issues in Thrombophilia. Arch Pathol Lab Med. 2002; 126(11):1277-1433. 12421135
De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.N Engl J Med. 1999 Sep 9; 341(11):801-806. 10477778
Grody WW, Griffin JH, Taylor AK, et al. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med. 2001 Mar-Apr; 3(2):139-148. 11280951
Laffan M, Tuddenham E. Thrombophilia: An expanding group of genetic defects that predispose to thrombosis. Mol Med Today. 1997 Jul; 3(7):303-309. 9257298
Reich LM, Bower M, Key NS. Role of the geneticist in testing and counseling for inherited thrombophilia.Genet Med. 2003 May-Jun; 5(3):133-143. 12792420
Van Cott EM, Soderberg BL, Laposata M. Activated protein C resistance, the factor V Leiden mutation, and a laboratory testing algorithm. Arch Pathol Lab Med. 2002 May; 126(5):577-582. 11958664
Voelkerding KV. Resistance to activated protein C and a novel factor V gene mutation. Clin Lab Med. 1996 Mar; 16(1):169-186 (review). 8867589


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
511154 Factor V Leiden Mutation 21667-1 511155 Factor V Leiden 21667-1

For Providers

Please login to order a test

Order a Test

© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at